The Richest Woman in the World: How Gina Rinehart Earns her Billions
Preserve Your Budget by Freezing Foods -- Savings ExperimentFor speculative investors aware of the risks associated with a development stage drug company, Karim Rahemtulla looks to Medivation (NASDAQ: MDVN), a play on development of a drug to treat Alzheimer's.
In his Xcelerated Profits Report, the advisor explains, "Medivation continues to make good clinical trial progress with its Dimebon drug for Alzheimer's Disease.
"The firm received some mainstream media attention at the recent International Conference on Alzheimer's Disease (ICAD) in Vienna. Reuters, Forbes and Bloomberg all reported that Dimebon is changing the way scientists think about Alzheimer's.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
